米拉贝隆(Mirabegron) - 药物靶点：GP IIb/IIIa_在研适应症：神经源性逼尿肌过度活动，膀胱过度活动症综合征，膀胱过度活动症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Betmiga PR、Mirabegron (USAN/JAN)、Myrbetriq Granules

+ [8]

靶点

GP IIb/IIIa

作用机制

GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂)

治疗领域

泌尿生殖系统疾病

在研适应症

神经源性逼尿肌过度活动膀胱过度活动症综合征膀胱过度活动症

非在研适应症

紫绀和肝病间质性膀胱炎勃起功能障碍+ [5]

原研机构

Astellas Pharma, Inc.

在研机构

Astellas Pharma Europe Ltd.Astellas Pharma Global Development, Inc.

Astellas Pharma, Inc.

+ [1]

非在研机构

Astellas Pharma US, Inc.

安斯泰来制药（中国）有限公司

最高研发阶段批准上市

首次获批日期

日本 (2011-07-01),

膀胱过度活动症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C21H24N4O2S

InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N

CAS号223673-61-8

关联

236

项与米拉贝隆相关的临床试验

NCT05713799 / Not yet recruiting临床2期IIT

Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity

Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

开始日期2024-11-25

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT06534762 / Recruiting临床2期IIT

Efficacy and Safety of Milaberon in Combination With Standard Therapy in Advanced Solid Tumors: an Open, Multicenter, Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the clinical commonly used dose. The main adverse reactions of this product are urinary tract infection and rapid heartbeat. In the clinical study, we will focus on the urine routine and heart-related adverse events of the subjects, and deal with the adverse events in time.
Subjects were given mirabeeron 100mg/day orally once a day in the morning until disease progression. When there are related or possible related side effects of the study drug mirabeeron, and according to NCI-CTCAE V 5.0, when subjects have more than or equal to grade 3 related toxicity, the administration should be delayed until grade 2 or lower to baseline, and the dose will be reduced by 50%, and subsequent dose increase is not allowed. If the pre-dose criteria are not met within 28 days, the drug will be permanently discontinued.

开始日期2024-07-15

申办/合作机构

浙江省人民医院

CTR20240866 / CompletedN/A

米拉贝隆缓释片在中国健康志愿者中餐后状态下生物等效性试验

主要目的：在中国健康受试者中评价高脂高热量餐后状态单次给药浙江普利药业有限公司生产的米拉贝隆缓释片（受试制剂，50mg）与美国上市米拉贝隆缓释片（参比制剂，Myrbetriq®，50mg）的人体生物等效性次要目的：在中国健康受试者中观察高脂高热量餐后状态单次给药米拉贝隆缓释片受试制剂和参比制剂的安全性

开始日期2024-07-01

申办/合作机构

浙江普利药业有限公司

100 项与米拉贝隆相关的临床结果

登录后查看更多信息

100 项与米拉贝隆相关的转化医学

登录后查看更多信息

100 项与米拉贝隆相关的专利（医药）

登录后查看更多信息

861

项与米拉贝隆相关的文献（医药）

2024-12-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Computational insights into human UCP1 activators through molecular docking, MM-GBSA, and molecular dynamics simulation studies

Article

作者: Shukla, Ravi ; Paul, Atish T. ; Jagtap, Utkarsh A. ; Rathod, Sanket ; Jagtap, Utkarsh A ; Paul, Atish T

The prevalence of obesity is rapidly increasing worldwide. Brown adipose tissue activates uncoupling protein 1 (UCP1) to generate heat through bypassing ATP synthesis, offering a potential target for obesity treatment. Targeting UCP1 activation to induce thermogenesis through small molecules presents a promising approach for obesity management. In this study, molecular docking of UCP1 activators, using 2,4-dinitrophenol (DNP) as a reference ligand (PDB ID: 8J1N, docking score: -5.343 kcal/mol), identified seven top-scoring compounds: naringin (-7.284 kcal/mol), quercetin (-6.661 kcal/mol), salsalate (-6.017 kcal/mol), rhein (-5.798 kcal/mol), mirabegron (-5.535 kcal/mol), curcumin (-5.479 kcal/mol), and formoterol (-5.451 kcal/mol). Prime MM-GBSA calculation of the top-scored molecule (i.e., naringin) in the docking study showed ΔGBind of -70.48 kcal/mol. Key interactions of these top 7 activators with UCP1 binding pocket residues Trp280, Arg276, Glu190, Arg83, and Arg91 were observed. Molecular dynamics simulations performed for 100 ns confirmed complex stability, with RMSD values below 6 Å. Additionally, most activators showed favorable intestinal absorption (>90 %) and lipophilicity (LogP 2-4), with pKa values supporting their pharmacological potential as UCP1-targeting therapeutics for obesity. These findings provide a foundation for designing potent UCP1 activators by integrating docking scores, interaction profiles, statistical profiles from MD simulations, and physicochemical assessments to develop effective anti-obesity therapies.

2024-12-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phenotypic characteristics of adipocyte-like cells generated from C2C12 myoblasts cultured with chicken serum

Article

作者: Ijiri, Daichi ; Katafuchi, Ayumi ; Kohrogi, Rukana ; Tomonaga, Shozo ; Shimamoto, Saki ; Nakamura, Kiriko ; Nakashima, Kazuki ; Ohtsuka, Akira

The aim of this study was to clarify the transcriptional and metabolic characteristics of C2C12 myoblasts cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 20 % chicken serum (CHS) (C2C12-CHS cells) compared with C2C12 myoblasts cultured in DMEM containing 20 % fetal bovine serum (FBS) (C2C12-FBS cells). After 3 days of culture, C2C12-CHS cells showed a marked accumulation of lipid droplets, accompanied by increased expression levels of brown adipocyte-related genes (i.e., Bmp7, Prdm16, Ucp1, Cidea, Pgc1α, Cox7a1, Cox8, and β₃-adorenoceptor). Furthermore, stimulation of β₃-adorenoceptor by its selective agonist, mirabegron, increased the mRNA expression of Ucp1 and Pgc1α in C2C12-CHS cells. Wide-targeted metabolomic analysis performed by gas chromatography-tandem mass spectrometry revealed that the metabolic profile of C2C12-CHS cells was obviously different to that of C2C12-FBS cells. Additionally, the metabolomic analysis indicated that β₃-adrenoceptor stimulation by mirabegron upregulated energy metabolism in C2C12-CHS cells as seen in brown adipocytes. These results suggest that C2C12-CHS cells may differentiate into brown adipocyte-like cells, accompanied by increased functional β₃-adrenoceptor.

2024-11-30·Rapid Communications in Mass Spectrometry

Development of an UPLC‐MS/MS approach to detect and quantify N‐nitroso mirabegron in mirabegron

Article

作者: Senadi, Gopal Chandru ; Prabhu, Rakesh Chandrakant ; Uppala, Ravi ; Devikala, Sundaramurthy ; Maruthapillai, Arthanareeswari ; Venkatasubbaiah, Bandaru

In the mirabegron (MIR) synthesis, the N‐nitroso mirabegron (NNM) is obtained during synthetic process of MIR; water is being used in reaction under acidic condition. Nitrite source is from water, and secondary amine source is from MIR as it has secondary amine; NNM is generated as an impurity during the synthesis of MIR. The presence of NNM in MIR could potentially affect its effectiveness. The purpose of this study was to establish a Ultra‐performance liquid chromatography‐mass spectrometry/mass spectrometry (UPLC‐MS/MS) methodology to identify NNM in MIR samples. The method for NNM analysis was developed on Acquity HSS T3 (100*2.1) mm 1.8 μm column with gradient elution using mobile phase consisted of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in methanol (mobile phase B). Mass spectrometer with electrospray ionization operated in the MRM mode was used in the analysis of NNM (m/ z 426.20 → 170.00). The UPLC‐MS/MS methodology proposed showed a good linearity (0.02 to 0.72 ppm), good system precision (RSD = 0.57%), good method precision (RSD = 0.87%), acceptable accuracy (94.5–116.5%), low detection limit (0.006 ppm) and low quantification limit (0.02 ppm) for NNM. The UPLC‐MS/MS methodology proposed can be utilized to assess the quality of MIR sample for the presence of NNM impurity.

97

项与米拉贝隆相关的新闻（医药）

2024-11-15

·adalvo.com

Adalvo Announces Successful EU Approval for Mirabegron 50mg Prolonged-Release Tablets

Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets. Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. According to IQVIA, Mirabegron achieved approximately $3.3Bn in global sales in 2023, with a 3-year CAGR of 2%. Additionally, registrations for Mirabegron 25mg are currently ongoing, demonstrating Adalvo's commitment to providing a wide range of treatment options. Adalvo’s success in securing this approval reflects our capabilities to develop complex, differentiated products. Building on the success of Mirabegron, Adalvo is also progressing well with the development of Mirabegron+Solifenacin, further expanding our portfolio and enhancing treatment options for patients. There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. Partner Up Now! Click Here To Get In Touch! © 2022-2024 Adalvo Limited. All right reserved

上市批准

2024-11-04

·安斯泰来中国

安斯泰来公布2024财年前6个月财务业绩

安斯泰来制药集团（TSE:4503）近日发布了2024财年前6个月全球财务业绩（2024财年前6个月为2024年4月1日至2024年9月30日）。用于前列腺癌治疗的XTANDI、用于尿路上皮癌治疗的PADCEV以及用于急性髓系白血病治疗的XOSPATA销售额均表现出稳健增长。此外，用于缓解更年期血管舒缩症状的VEOZAH和用于治疗与年龄相关的黄斑变性所致地理萎缩的IZERVAY，这两款于上财年推出的产品也推动了收入的增长。最终2024财年前六个月营业收入为：9,356亿日元，较上一财年同期同比增长22.0%，核心营业利润为1,831亿日元，同比增长36.2%。主要增长引擎 XTANDI 销售额同比增长25.1% 达到4,517亿日元 PADCEV 销售额同比增长130.5% 达到754亿日元 XOSPATA 销售额同比增长32.3% 达到348亿日元 VYLOY 2024年6月在日本上市，销售额大幅增长，达到12亿日元 VEOZAH1 全球销售额稳步增长达到148亿日元 Betanis /Myrbetriq /BETMIGA 销售额同比减少19.1% 销售额为775亿日元 Prograf2 全球销售额同比增长3.9% 达到1,039亿日元 IZERVAY 在美国上市，销售额超出预期达到281亿日元稳定投资未来成长 2024财年前6个月的研发费用为1,723亿日元，同比增长21.4%。中国区3稳步增长得益于XTANDI、XOSPATA等包括肿瘤药在内的产品组合展现的强大潜力。中国商业区实现收入377亿日元，为全球业绩增长贡献了力量。安斯泰来将致力于实现我们的愿景：将科学的进步转变为患者的价值，并对未来的稳定增长充满信心。延伸阅读中国国家药品监督管理局批准备思复（注射用维恩妥尤单抗）用于治疗局部晚期或转移性尿路上皮癌中国国家药品监督管理局批准安可坦（XTANDI，恩扎卢胺）治疗转移性激素敏感性前列腺癌的新适应症日本厚生劳动省批准备思复（维恩妥尤单抗）联合可瑞达（帕博利珠单抗）用于一线治疗不可根治性切除的尿路上皮癌安斯泰来 VYLOY (zolbetuximab-clzb) 获美国 FDA 批准用于治疗晚期胃和胃食管交界处(GEJ)腺癌注释 1- VEOZAH: Approved as “VEOZA” in ex-US 2-PROGRAF: Includes ADVAGRAF, GRACEPTOR, and ASTAGRAF XL. 3-中国区包括:中国大陆地区和香港地区

财报抗体药物偶联物

2024-11-01

·药闻康策

官宣！第十批国采涉及62个大品种、263个品规

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策第十批集采终于官宣了！ 11月1日，联合采购办公室发布通知，第十批国家组织药品集中采购药品即将分阶段开展企业药品基础信息填报工作，第十批国家集采终于正式启动。第十批集采拟纳入62个品种、263个品规（以编号计），创历次集采之最。从销售规模看，62个品种2023年在中国公立医疗机构终端的销售额合计接近550亿元，其中超10亿大品种有20余个；纳入门槛提升至7家及以上，其中38个品种符合申报资格企业数达10家及以上，齐鲁制药、科伦药业、倍特药业等为主力。相信第十批集采开标后相关品种市场格局将迎来新一轮洗牌。 550亿市场激战在即 6个超10亿品种承压第十批集采或将成为历次最“卷”的一次国采。数据显示，拟纳入第十批集采的62个品种2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售规模合计接近550亿元，其中超10亿大品种有20余个，6个品种销售额尚未突破1亿元。 62个品种销售额分布情况从治疗领域看，62个品种涵盖10个治疗大类，集中在心脑血管系统药物、全身用抗感染药物、消化系统及代谢药三大治疗领域，涉及的品种数分别达12、10、10个。数据显示，上述三个治疗大类2023年在中国公立医疗机构终端的销售额均超过1000亿元。在消化系统及代谢化药领域，包括4个糖尿病用药、1个矿物质补充剂、1个胃肠解痉药/抗胆碱药/胃动力药、1个治疗便秘的药物、1个治疗与胃酸分泌相关疾病的药物、1个维生素类及1个止吐药/止恶心药。拟纳入第十批集采的消化系统及代谢化药注：销售额低于1亿元用*代表 10个品种2023年在中国公立医疗机构终端的销售额合计超过100亿元，其中西格列汀口服常释剂型超20亿元，依帕司他口服常释剂型、利格列汀口服常释剂型、间苯三酚注射剂、复方聚乙二醇电解质散、注射用盐酸罗沙替丁醋酸酯等5个产品均超10亿元。 5大品种达20家以上齐鲁、倍特、科伦为主力从竞争情况看，西格列汀口服常释剂型为最“卷”品种，目前符合申报资格企业数已超过30家；此外，帕拉米韦注射剂、间苯三酚注射剂、乙酰半胱氨酸吸入剂、氨溴索口服液体剂均超20家，地氯雷他定口服液体剂、舒更葡糖注射剂达19家，艾司洛尔注射剂达18家。磷酸西格列汀片属于DPP-4抑制剂，用于改善2型糖尿病患者的血糖控制。该产品近年来在中国公立医疗机构终端的销售额逐年上涨，2023年突破20亿元，在口服糖尿病化药产品格局中排位第二。该原研药专利于2022年7月到期，正大天晴药业等企业的产品已于2022下半年开始上市销售，瓜分默沙东市场份额。目前有38家药企的磷酸西格列汀片以新注册分类报产，其中有32家药企（31家集团）已顺利获批并视同过评。近年来中国公立医疗机构终端磷酸西格列汀片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从企业纳入品种情况看，齐鲁制药、科伦药业、倍特药业、复星医药、石家庄四药、扬子江药业、石药集团、远大健康、华润医药、正大制药将为“主力军”，目前分别有22、19、18、18、17、17、15、13、12、10个过评品种在列。拟纳入品种数达10个及以上的国内企业齐鲁制药以22个品种领跑，包括11个注射剂、9个口服常释剂型及2个缓释控释剂型，其中瑞戈非尼片、马昔腾坦片、盐酸多柔比星脂质体注射液、米拉贝隆缓释片等为2024年新获批品种。科伦药业以19个品种排位第二，包括12个注射剂、6个口服常释剂型及1个缓释控释剂型等，其中瑞戈非尼片、艾地骨化醇软胶囊、己酮可可碱注射液、间苯三酚注射液等为2024年新获批品种。倍特药业、复星医药以18个品种并列第三，其中倍特药业有15个注射剂、3个口服常释剂型在列，重酒石酸去甲肾上腺素注射液、左西孟旦注射液、依帕司他片、重酒石酸间羟胺注射液、钆特酸葡胺注射液等为2024年新获批品种。附：报量品种竞争格局（数据截止时间：10月23日） (来源:医药经济报作者:茗瑶）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

100 项与米拉贝隆相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09535	米拉贝隆	G04BD12	DB08893

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经源性逼尿肌过度活动	欧盟	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	冰岛	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	列支敦士登	Astellas Pharma Europe Ltd.	2024-09-05
神经源性逼尿肌过度活动	挪威	Astellas Pharma Europe Ltd.	2024-09-05
膀胱过度活动症综合征	欧盟	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	冰岛	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	列支敦士登	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症综合征	挪威	Astellas Pharma Europe Ltd.	2012-12-20
膀胱过度活动症	日本	Astellas Pharma, Inc.	2011-07-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间质性膀胱炎	临床3期	美国	Astellas Pharma Global Development, Inc.	2016-08-01
尿失禁	临床3期	美国	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	亚美尼亚	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	澳大利亚	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	奥地利	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	比利时	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	加拿大	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	捷克	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	丹麦	Astellas Pharma Europe Ltd.	2013-07-10
尿失禁	临床3期	芬兰	Astellas Pharma Europe Ltd.	2013-07-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04766021 (CTgov)	临床1/2期	-	30	Placebo (Placebo)	鑰夢製蓋構鏇選齋憲憲(製願艱襯獵餘網淵壓憲) = 鬱簾顧憲選壓鏇廠艱網顧積鏇積遞製襯簾窪夢 (簾製鏇窪襯糧鏇淵願壓, 繭餘襯願襯餘夢蓋選網 ~ 醖窪膚範製繭壓艱淵艱) 更多	-	2024-07-12
				Mirabegron (100 mg Mirabegron)	鑰夢製蓋構鏇選齋憲憲(製願艱襯獵餘網淵壓憲) = 淵壓網鏇鏇窪醖糧醖淵顧積鏇積遞製襯簾窪夢 (簾製鏇窪襯糧鏇淵願壓, 襯願築獵鬱糧鏇網網蓋 ~ 憲襯鏇壓獵蓋襯壓簾鏇) 更多
PD07-09 (AUA2024)	N/A	-	-	Mirabegron	積餘憲醖蓋觸膚憲鹽餘(糧觸選膚觸鏇糧餘衊夢) = 壓襯製蓋鹽艱構築鹹網糧餘鏇壓遞網齋窪窪夢 (壓襯繭窪窪積網衊網衊 )	积极	2024-05-01
				Anticholinergics	積餘憲醖蓋觸膚憲鹽餘(糧觸選膚觸鏇糧餘衊夢) = 獵壓網鏇窪網壓網鏇觸糧餘鏇壓遞網齋窪窪夢 (壓襯繭窪窪積網衊網衊 )
NCT01876433 (Pubmed) 人工标引	临床2期	射血分数降低的心力衰竭	57	Mirabegron (300 mg/day)	製壓壓簾餘網簾壓製鏇(構膚醖選構鏇願糧襯選) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 獵衊衊鬱鹹衊觸網衊網 (構夢壓願積餘網簾鏇獵 ) 更多	积极	2024-03-05
				Placebo
NCT04641975 (Dolphin, CTgov)	临床3期	膀胱过度活动症	26	Mirabegron (Mirabegron (5 to < 12 Years))	艱鹹繭網顧膚鬱壓衊憲(夢鬱廠觸簾淵願憲鏇鹽) = 壓鏇顧壓憲顧夢膚鏇蓋憲衊獵築鬱鑰衊壓糧艱 (鹽夢製鑰夢範夢遞願衊, 觸餘繭艱蓋積鏇醖餘構 ~ 壓襯餘繭夢觸齋觸築獵) 更多	-	2023-12-28
				Placebo (Placebo (5 to < 12 Years))	艱鹹繭網顧膚鬱壓衊憲(夢鬱廠觸簾淵願憲鏇鹽) = 願願膚鏇遞淵艱鹽顧觸憲衊獵築鬱鑰衊壓糧艱 (鹽夢製鑰夢範夢遞願衊, 醖鏇餘網糧鬱構鹽窪艱 ~ 糧衊製繭醖鹽鏇遞繭鏇) 更多
NCT02599480 (Beta3-LVH, Pubmed \| JAMA Cardiol)	临床2期	心脏病	296	Mirabegron 50 mg/d	選顧窪憲鹹鹹糧鹽顧獵(積齋顧齋糧鑰繭淵鹹鏇) = 獵觸選獵願鏇淵鬱鏇觸艱鏇願鹹夢築鏇獵積艱 (憲獵醖艱蓋蓋積鹹遞網, -0.15 ~ 2.74)	不佳	2023-11-01
NCT02086188 (MIRROR, CTgov)	临床4期	尿急 \| 多发性硬化症 \| 膀胱过度活动症	28	Mirabegron (Mirabegron)	遞膚憲鏇遞獵艱願襯夢(築製糧鬱膚觸醖衊鑰製) = 廠獵壓壓鹹壓選遞糧獵窪壓艱構鏇壓淵獵餘獵 (廠壓憲築製顧襯鹽齋顧, 餘艱蓋構顧鹽製齋簾繭 ~ 襯製構衊製簾憲願齋糧) 更多	-	2023-10-18
				Placebo (Placebo)	遞膚憲鏇遞獵艱願襯夢(築製糧鬱膚觸醖衊鑰製) = 簾衊網網夢鹽夢襯憲鏇窪壓艱構鏇壓淵獵餘獵 (廠壓憲築製顧襯鹽齋顧, 夢製衊憲鹽蓋鏇壓艱獵 ~ 鹹襯選齋選範壓顧壓蓋) 更多
NCT02462837 (CTgov)	临床2期	疼痛 \| 下尿路症状 \| 膀胱过度活动症	11	Mirabegron (Treatment Arm)	顧餘積糧齋積糧顧壓鏇(願糧糧選積壓淵觸襯艱) = 衊襯齋鑰糧願範鏇繭觸簾範繭簾網膚積膚憲淵 (願願壓艱衊鹹簾鹽製鹽, 顧鏇艱淵衊範壓鏇遞衊 ~ 觸積衊鹽齋繭觸鹽艱鏇) 更多	-	2023-06-13
				Placebo (Placebo Arm)	顧餘積糧齋積糧顧壓鏇(願糧糧選積壓淵觸襯艱) = 鹽蓋構壓餘齋選觸鹹遞簾範繭簾網膚積膚憲淵 (願願壓艱衊鹹簾鹽製鹽, 鹹繭憲鹽積繭觸壓襯積 ~ 醖窪廠餘範餘鏇醖憲夢) 更多
PD14-07 (AUA2023)	N/A	-	-	Mirabegron	構顧選獵醖憲醖遞鏇淵(夢夢選窪壓選繭齋鏇憲) = 窪顧觸築繭壓網鏇鑰製壓壓網艱顧夢範顧糧壓 (艱衊夢網壓願願衊膚齋 ) 更多	-	2023-04-01
AUA2023	N/A	慢性前列腺炎	-	Alpha blockers	鹽衊齋鬱願膚膚繭構襯(選簾廠襯鬱蓋淵網艱衊) = 衊範積糧鑰觸鏇餘鑰廠壓築範簾壓獵糧膚顧選 (壓選艱鑰壓鹽網膚艱獵 )	-	2023-04-01
				Placebo	鹽衊齋鬱願膚膚繭構襯(選簾廠襯鬱蓋淵網艱衊) = 顧憲遞獵夢餘積鹽淵網壓築範簾壓獵糧膚顧選 (壓選艱鑰壓鹽網膚艱獵 )
NCT04562090 (CTgov)	临床4期	急迫性尿失禁 \| 膀胱过度活动症	249	mirabegron (Mirabegron 50 mg)	壓網鏇膚餘範築醖鏇憲(願糧淵蓋壓鑰構選顧鬱) = 獵願醖構淵鏇膚憲蓋壓製顧齋願膚襯鏇餘淵顧 (憲衊觸鹽艱繭鹽衊鹹醖, 繭網築鹽廠範構鏇構範 ~ 蓋齋範夢範鬱網夢顧鹽) 更多	-	2023-03-29
				mirabegron (Mirabegron 25 mg)	製餘選觸構餘膚鑰蓋繭(夢鹹簾築獵簾遞獵鹹選) = 鹽廠糧繭鹽廠積構築繭夢鏇夢醖衊蓋鏇構鬱襯 (鏇遞夢鬱繭繭夢獵構範, 蓋繭構艱選構蓋鹹鹽製 ~ 齋構鹽夢窪顧鬱齋鹹獵) 更多